Key facts
- CardioMech’s last known valuation is $37.7M (Aug 2020).
- It has raised $59.2M; the latest was Later Stage VC ($17.6M) in Apr 2025.
- Notable investors include Investinor, The ECI Group, Fourth Element Capital, Hadean Ventures, Thornapple River Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CardioMech
- ·The full record, as it builds
Funding rounds
No funding rounds for CardioMech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CardioMech
Developer of catheter-based technology designed to provide an alternative to open-heart cardiac surgery. The company's therapy helps in the placement of artificial chords in the heart via a catheter to reduce or eliminate mitral regurgitation without opening the chest, stopping the heart, or going on a heart-lung bypass, enabling surgeons to treat patients with moderate to severe or severe symptomatic RMD.
- Sector
- Healthcare
- HQ
- Trondheim, Norway
- Founded
- 2015
- Employees
- 9
- Website
- cardiomech.com/
- Ownership
- Privately Held (backing)
CardioMech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CardioMech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CardioMech in its N-PORT filings yet. We sweep new filings monthly.